Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.

Bellone, S

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. [electronic resource] - British journal of cancer Apr 2012 - 1543-50 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1532-1827

10.1038/bjc.2012.132 doi


Aged
Aged, 80 and over
Antibodies, Monoclonal--immunology
Antibodies, Monoclonal, Humanized--therapeutic use
Antibody-Dependent Cell Cytotoxicity
CD55 Antigens--chemistry
CD59 Antigens--chemistry
Complement Activation
Cystadenocarcinoma, Serous--genetics
Cytotoxicity, Immunologic
Down-Regulation
Female
Flow Cytometry
Humans
In Situ Hybridization, Fluorescence
Membrane Cofactor Protein--genetics
Middle Aged
Prognosis
RNA, Small Interfering--genetics
Real-Time Polymerase Chain Reaction
Receptor, ErbB-2--genetics
Trastuzumab
Uterine Cervical Neoplasms--genetics